On Jun 29, 2018 Zafgen Inc (NASDAQ:ZFGN) Sellers Increased Their Shorts By 13.18%

June 29, 2018 - By Clara Lewis

Zafgen, Inc. (NASDAQ:ZFGN) Corporate Logo

Change of 13.18% for Zafgen Inc (NASDAQ:ZFGN)’s shares shorted was registered. In June was issued ZFGN’s total 677,600 shares shorted by FINRA. The 598,700 previous shares are up with 13.18%. Zafgen Inc (NASDAQ:ZFGN) has 171,500 shares average volume. It’ll cost 4 days for ZFGN to restore its previous position. Zafgen Inc’s shares shorted float is 3.01%.

Ticker’s shares touched $9.98 during the last trading session after 3.96% change.Zafgen, Inc. is uptrending after having risen 60.78% since June 29, 2017. ZFGN has 539,372 volume or 114.87% up from normal. ZFGN outperformed the S&P500 by 48.21%.

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from metabolic diseases comprising type 2 diabetes and obesity.The firm is valued at $275.08 million. The companyÂ’s lead product candidate is ZGN-1061, a fumagillin-class MetAP2 inhibitor administered by subcutaneous injection, which is in Phase 1 clinical trial and profiled for its utility in the treatment of metabolic diseases.Last it reported negative earnings.

Zafgen, Inc. (NASDAQ:ZFGN) Ratings Coverage

A total of 2 analysts rate Zafgen (NASDAQ:ZFGN) as follows: 1 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 50% are bullish. (NASDAQ:ZFGN) has 2 ratings reports on Jun 29, 2018 according to StockzIntelligence.

For more Zafgen, Inc. (NASDAQ:ZFGN) news announced briefly go to: Nasdaq.com, Benzinga.com, Globenewswire.com, Nasdaq.com or Globenewswire.com. The titles are as follows: “Mid-Afternoon Market Update: NASDAQ Down Over 2.5%; Xerium Technologies Shares Spike Higher” announced on June 25, 2018, “Benzinga’s Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut” on June 28, 2018, “Zafgen Announces Pricing of Offering of Common Stock” with a publish date: June 28, 2018, “Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to …” and the last “Zafgen Announces Proposed Offering of Common Stock” with publication date: June 27, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: